Index of drugs

Active immunization of adolescents (from the age of 11) and adults exposed to the drenching of meningitis (Neisseria meningitidis) from serogroups A, C, W135 and Y, to prevent invasive disease. The vaccine should be used in accordance with official official recommendations.

1 dose of vaccine (0.5 ml) contains: 10 μg of group A meningococcal oligosaccharide, 5 μg of group C meningococcal oligosaccharide, 5 μg of W135 meningococcal group oligosaccharide and 5 μg of group Y meningococcal oligosaccharide, conjugated to CRM protein₁₉₇ Corynebacterium diphtheriae.

A vaccine conjugated against meningococcal group A, C, W135 and Y. Administration of the vaccine results in the production of serotonin-specific anti-carotid antibodies with bactericidal activity, as demonstrated by human complementation (hSBA) tests.

Hypersensitivity to the active substance or to any of the excipients (including diphtheria toxoid - CRM₁₉₇) or the occurrence of life-threatening reactions after previous administration of a vaccine containing similar ingredients. ACUTE, severe disease with fever (vaccination should be postponed). Do not administer intravascularly, subcutaneously or intradermally.

Vaccination should be preceded by the collection of an accurate medical history (with particular reference to previous vaccinations and side effects that could have been caused by them) and physical examination. Appropriate supervision and treatment should be possible in the event of anaphylactic reactions following administration of the vaccine. The vaccine does not provide protection against infections caused by other, non-existing serotypesN. meningitidis. As with other vaccines, the protective immune response may not occur in all vaccinated individuals. Reduction of bactericidal serum against serotype A has been shown (the clinical significance of this observation is unknown). Safety information on the booster dose is limited, however if you suspect the risk of meningococcal Group A infection and if a minimum one year has elapsed since the last vaccination, a booster dose may be considered. No data on vaccination in prophylaxis after exposure. HIV infection is not a contraindication to the administration of a vaccine, however, in immunocompromised people, vaccination may not trigger an adequate immune response. In patients with complement deficiencies and patients with asplenia (functional or anatomical), there may be no immune response to group A, C, W135 and Y conjugated vaccines. Due to the risk of hematoma following intramuscular administration, consideration should be given to administering the vaccine to patients with hemorrhagic disorders or those receiving anticoagulant therapy. There are limited data on the use of the vaccine in people aged 56-65; no data on persons aged> 65 years. The syringe cap contains 10% dry natural rubber, so you should consider the risk / benefit ratio before giving the vaccine to patients with known hypersensitivity to latex.

The direct or indirect harmful effects of the vaccine on pregnancy, embryonal / fetal development, parturition or postnatal development have not been demonstrated. Given the severe course of infectionNeisseria meningitidis from serogroups A, C, W and Y, in the case of an obvious risk of exposure, pregnancy is not a contraindication to vaccination. The vaccine can be used during breastfeeding.

Very common: headache, nausea, muscle pain, pain at the injection site, erythema at the injection site (≤50 mm), induration at the injection site (≤ 50 mm), malaise. Common: rash, joint pain, erythema at the injection site (> 50 mm), induration at the injection site (> 50 mm), fever ≥38st.C, chills. Uncommon: dizziness, pruritus at the injection site.Rarely: hypersensitivity reactions, fainting, dizziness, and cellulitis at the injection site.

Intramuscularly (preferably in the deltoid muscle). Adults and children aged ≥11 years: 0.5 ml (1 dose). The necessity or timing of a booster dose of vaccine has not been established.